Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208208 · ClinicalTrials.gov registry record · Phase 4
Geodon (Ziprasidone) for Posttraumatic Stress Disorder
A Phase 4 study, sponsored by Creighton University.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT00208208 is a Phase 4 study that has completed, run by Creighton University. The registered enrollment target is 80 participants.
The verdict
NCT00208208, a Phase 4 study, has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).
Interventions
- DRUG Ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208208
The ClinicalTrials.gov registry entry for NCT00208208 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creighton University, which has 98 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ziprasidone is the first listed.
NCT00208208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00208208 about?
NCT00208208 is a clinical study titled "Geodon (Ziprasidone) for Posttraumatic Stress Disorder". Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiven...
What is the current status of trial NCT00208208?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2002-12. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00208208?
The interventions under investigation include: Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00208208?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.